MX2022011768A - Forma cristalina del profarmaco de nitroxolina, la composicion farmaceutica que la contiene, y el metodo de preparacion y aplicacion de la misma. - Google Patents
Forma cristalina del profarmaco de nitroxolina, la composicion farmaceutica que la contiene, y el metodo de preparacion y aplicacion de la misma.Info
- Publication number
- MX2022011768A MX2022011768A MX2022011768A MX2022011768A MX2022011768A MX 2022011768 A MX2022011768 A MX 2022011768A MX 2022011768 A MX2022011768 A MX 2022011768A MX 2022011768 A MX2022011768 A MX 2022011768A MX 2022011768 A MX2022011768 A MX 2022011768A
- Authority
- MX
- Mexico
- Prior art keywords
- crystal form
- application
- preparation
- pharmaceutical composition
- composition containing
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 5
- RJIWZDNTCBHXAL-UHFFFAOYSA-N nitroxoline Chemical compound C1=CN=C2C(O)=CC=C([N+]([O-])=O)C2=C1 RJIWZDNTCBHXAL-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005131 nitroxoline Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 238000009776 industrial production Methods 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 238000010186 staining Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una forma cristalina de un profármaco de nitroxolina, una composición farmacéutica que contiene el mismo y, por lo tanto, un método de preparación y una aplicación del mismo. Un patrón de difracción de rayos X en polvo de una forma cristalina A comprende picos característicos a 5.74±0.2o, 6.78±0.2°, 10.86±0.2º, 13.54±0.2°, 16.70±0.2° y 22.65±0.2°; un patrón de difracción de rayos X en polvo de un cristal de forma B comprende picos característicos a 5.44±0.2°, 10.90±0.2°, 14.09±0.2°, 16.17±0.2°, 17.92±0.2°, 20.66±0.2°, and 23.13±0.2°. En comparación con la nitroxolina, las formas cristalinas A y B en la presente solicitud no son propensas a mancharse, tienen bajos requisitos de equipo y son más adecuadas para la producción industrial; las propiedades estables son más propicias para el control de calidad en la producción industrial y la estabilidad en la eficacia del fármaco.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010236147 | 2020-03-30 | ||
| PCT/CN2021/084057 WO2021197338A1 (zh) | 2020-03-30 | 2021-03-30 | 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011768A true MX2022011768A (es) | 2022-10-18 |
Family
ID=77929313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011768A MX2022011768A (es) | 2020-03-30 | 2021-03-30 | Forma cristalina del profarmaco de nitroxolina, la composicion farmaceutica que la contiene, y el metodo de preparacion y aplicacion de la misma. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230119296A1 (es) |
| EP (1) | EP4129983A4 (es) |
| JP (1) | JP2023519276A (es) |
| KR (1) | KR20230008047A (es) |
| CN (1) | CN115427397B (es) |
| AU (1) | AU2021245884A1 (es) |
| BR (1) | BR112022017437A2 (es) |
| CA (1) | CA3171261A1 (es) |
| MX (1) | MX2022011768A (es) |
| TW (1) | TW202144329A (es) |
| WO (1) | WO2021197338A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202103134TA (en) * | 2018-09-29 | 2021-04-29 | Jiangsu Yahong Meditech Co Ltd | Nitroxoline prodrug and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3483081D1 (de) * | 1983-10-18 | 1990-10-04 | Ciba Geigy Ag | Verwendung von chinolinderivaten zum schuetzen von kulturpflanzen. |
| EP2350012B1 (en) * | 2008-10-06 | 2017-06-28 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
| US20130210821A1 (en) * | 2010-05-27 | 2013-08-15 | James E. Vath | Methods for Treating Obesity |
| SG11202103134TA (en) | 2018-09-29 | 2021-04-29 | Jiangsu Yahong Meditech Co Ltd | Nitroxoline prodrug and use thereof |
| CN111514142B (zh) * | 2020-05-29 | 2021-04-06 | 江苏亚虹医药科技股份有限公司 | 含硝羟喹啉前药的药物组合物及其制备方法和应用 |
| CN111646936A (zh) * | 2020-06-22 | 2020-09-11 | 江苏亚虹医药科技有限公司 | 芳香醚类化合物的制备方法 |
-
2021
- 2021-03-30 BR BR112022017437A patent/BR112022017437A2/pt unknown
- 2021-03-30 CN CN202180024008.XA patent/CN115427397B/zh active Active
- 2021-03-30 TW TW110111625A patent/TW202144329A/zh unknown
- 2021-03-30 CA CA3171261A patent/CA3171261A1/en active Pending
- 2021-03-30 WO PCT/CN2021/084057 patent/WO2021197338A1/zh unknown
- 2021-03-30 AU AU2021245884A patent/AU2021245884A1/en active Pending
- 2021-03-30 EP EP21781348.4A patent/EP4129983A4/en active Pending
- 2021-03-30 KR KR1020227036720A patent/KR20230008047A/ko unknown
- 2021-03-30 MX MX2022011768A patent/MX2022011768A/es unknown
- 2021-03-30 US US17/906,996 patent/US20230119296A1/en active Pending
- 2021-03-30 JP JP2022557933A patent/JP2023519276A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115427397A (zh) | 2022-12-02 |
| AU2021245884A1 (en) | 2022-09-29 |
| EP4129983A4 (en) | 2024-03-13 |
| JP2023519276A (ja) | 2023-05-10 |
| BR112022017437A2 (pt) | 2022-10-18 |
| US20230119296A1 (en) | 2023-04-20 |
| WO2021197338A1 (zh) | 2021-10-07 |
| KR20230008047A (ko) | 2023-01-13 |
| TW202144329A (zh) | 2021-12-01 |
| EP4129983A1 (en) | 2023-02-08 |
| CA3171261A1 (en) | 2021-10-07 |
| CN115427397B (zh) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010407A (es) | Benzotiofenos y compuestos relacionados como agonistas de sting. | |
| MX2023012361A (es) | Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo. | |
| MX2021016085A (es) | Derivados de benzisoxazol sulfonamida. | |
| JOP20220155A1 (ar) | مشتقات البيرازول مفيدة كعوامل مضادة للسرطان | |
| GEP20237568B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| NZ742200A (en) | Treatment of osteoarthritis | |
| MX2022011768A (es) | Forma cristalina del profarmaco de nitroxolina, la composicion farmaceutica que la contiene, y el metodo de preparacion y aplicacion de la misma. | |
| CA3057882A1 (en) | Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein | |
| GEP20053495B (en) | Polymorphs of Epothilone Analog, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof | |
| IL214086A (en) | Malt salt of n- {4 - {[7,6- bis (methyllaxy) quinoline-4-yl] oxy} phenyl) - n- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms for cancer treatment | |
| AU2020330570A8 (en) | Process of making CFTR modulators | |
| BR0212277A (pt) | Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor do ibat, e, composição farmacêutica | |
| MX2023006854A (es) | Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma. | |
| MX2021013817A (es) | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. | |
| CR20210216A (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
| AU2019375825A8 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
| MY195262A (en) | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-A]Pyrimidine Derivatives | |
| AU2018270520A1 (en) | Compounds for use as iron(III) MRI contrast agents | |
| MX2023004835A (es) | Metodo para la preparacion de la composicion cristalina y farmaceutica acido 1-(3-ciano-1-isopropil-indol-5-yl)pirazol-4-car boxilico que lo comprende. | |
| MX2020013291A (es) | Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis. | |
| MXPA05012679A (es) | Nuevos derivados de imidazoles, su preparacion y su uso como medicamento. | |
| MX2022010673A (es) | Nuevos compuestos macrociclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| MX2023003459A (es) | Nuevos compuestos. | |
| JP2017535510A5 (es) |